Trial Profile
Understanding Mechanisms of Acquired Resistance to BIBW2992.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 10 Mar 2017 Status changed from active, no longer recruiting to completed.
- 14 Nov 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jan 2017.
- 03 Nov 2014 Planned End Date changed from 1 Mar 2015 to 1 Mar 2017, according to ClinicalTrials.gov record.